Zoledronic Acid Kabi, 4mg/5ml Concentrate for Solution for Infusion

Manufacturer
FRESENIUS KABI AUSTRIA GMBH
 
Contents
Zoledronic acid
 
Indication
Hypercalcaemia of malignancy, Bone metastases associated with solid tumours, Osteolytic lesions associated with multiple myeloma.
 
Instruction
4 mg by infusion over at least 15 min 3-4 wkly. Co-admin oral Ca 500 mg and vit D 400 IU daily.
 
Drug interaction
Increased exposure of concomitant drugs eliminated by renal excretion (e.g. digoxin). Increased risk of hypocalcaemia w/ loop diuretics. Lowered serum Ca concentrations for prolonged periods w/ aminoglycosides. Increased risk of renal dysfunction w/ nephrotoxic agents.